- Recommendation ID
- HST8/3
- Question
Evidence on the progression of X-linked hypophosphataemia (XLH) over time and the long-term benefits of burosumab would also be valuable.
- Any explanatory notes
(if applicable) None
Source guidance details
- Comes from guidance
- Burosumab for treating X-linked hypophosphataemia in children and young people
- Number
- HST8
- Date issued
- October 2018
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/10/2018 |